SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks
Pharmos(PARS)
An SI Board Since November 1996
Posts SubjectMarks Bans Symbol
1491 8 0 PARS
Emcee:  Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
366 The biggest problem with a lot of potential drugs was safety. it looks that HUyosi s-3/19/1998
365 No question HU211 is a 'blockbuster', and will need a strategic allcrysball-3/19/1998
364 No, sorry but I'm just a poor Individual investor and can't spend alot Stephen D. Wilson-3/19/1998
363 Ariella, maybe both of us have jumped to the conclusion that the major side effRick Strange-3/19/1998
362 In head trauma HU211 is very promising.PARS also wants to prove it in stroke. yosi s-3/18/1998
361 Wellcome hopefully we all benefit and invest wiselyyosi s-3/18/1998
360 Tamoxiphen is currently used as adjuvent chemotherapy for breast cancer. Everyyosi s-3/18/1998
359 The next few months will be an interesting test of the new CFO at PARS. Histcrysball-3/18/1998
358 MY E-MAIL IS ISRAELROSEN@YAHOO.COMDavid Israel-Rosen-3/18/1998
357 Hi Ariella, Followed you over from the ABTX thread...hope you don't mind. sherine elgohary-3/18/1998
356 Yosi, can you bring me up to speed on tamoxiphen? I bought some more stock todaRick Strange-3/18/1998
355 Rick - that hypothetical rushed into my mind as soon as Alerex got its FDA apprAriella-3/18/1998
354 As a potent cortico-steroid chances are it will not be over the counter. As foyosi s-3/18/1998
353 Let us consider a hypothetical. A couple of years down the road Alerex lives upRick Strange-3/18/1998
352 David, I tried to e-mail information about my PARS holdings using the e-mail adRick Strange-3/18/1998
351 Same story as BTGC with the same news they went from 2 to 6 to 12. Just by geyosi s-3/18/1998
350 Yes the Trout Group is the current PR firm. One problem with a $2.50 stock erin4-3/18/1998
349 Dear Yosi, Isn't the Trout Group PARS' current PR firm? --AriellaAriella-3/18/1998
348 Thank you very much for the compliments and for the information. I look forwardAriella-3/17/1998
347 Glad to see a post from Neuro investment. as a subscriber I am waiting for theyosi s-3/17/1998
346 Actually, Pharmos was added to the NeuroInvestment Recommended List in the MarcNeuroInvestment-3/17/1998
345 erin4, How did you find out that Merrill Lynch analysts were meeting with PARSwisc-3/17/1998
344 The Pharmos staff is putting on a " road show" for different investerin4-3/17/1998
343 I do not know but would love to meet them. The last time I met Dr Aviv was a coDavid Israel-Rosen-3/17/1998
342 You are way ahead. first they got to finish phase 2 study another 6 month..yosi s-3/17/1998
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News